HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2019)... ... 2019 , ... CBD Hacker , the definitive guide to the CBD ... is the result of rigorous testing of more than 20 products, including third-party potency ... are looking for a fast-acting, effective delivery method for CBD. And the fact that ...
(Date:2/13/2019)... (PRWEB) , ... February 13, 2019 , ... ... 13, 2019, at the company’s annual member conference, Elevate 2019 at the Gaylord ... Intalere staff and members to explore potential partnerships driving improved quality of patient ...
(Date:2/13/2019)... ... 2019 , ... American Vision Partners, one of the largest ... new addition to their growing list of ophthalmology brands: Visage Aesthetics & Plastic ... practice. , Dr. Zachary Berbos, MD, FACS, and Dr. Grant Moore, ...
(Date:2/13/2019)... ... 2019 , ... Asana Recovery is accepting applications from college-bound or current college ... medical-related course of study in California, the $1,000 scholarship will be awarded to a ... treatment, and how it has led them to their chosen field of study. Applications ...
(Date:2/12/2019)... ... February 12, 2019 , ... Medical Device Risk Management, Prepare ... Feb. 19-20, 2019, Atlanta, GA , https://www.fdanews.com/mdriskmanagement , One week left ... on Jan. 22 , Risk management is just plain hard, complicated, conflicted, confusing. ...
Breaking Medicine News(10 mins):
(Date:2/14/2019)... ... February 14, 2019 , ... ... Radiology Associates (ARA), in Asheville, North Carolina. , “We are excited to ... opportunities available through Strategic Radiology,” said Arl Van Moore Jr, MD, Strategic Radiology ...
(Date:2/13/2019)... NEW YORK (PRWEB) , ... February 13, 2019 , ... ... $12.5 million grant from the National Institute on Aging, part of the National Institutes ... multidisciplinary projects in aging biology. , The program’s goals are to establish follicle-stimulating ...
(Date:2/13/2019)... ... February 13, 2019 , ... Sensible Surrogacy today ... opens possibilities for childless couples who are unable to afford the staggering cost ... been limited to North America or Eastern Europe for legal and secure surrogacy ...
Breaking Medicine Technology:
Cached News: